Tag Archives: Novartis

#FierceMadness pharma ad contest narrows: Pfizer, Bayer, Novartis, ViiV and Biohaven among the Elite Eight still standing

FierceMadess voters have spoken—and now, just an Elite Eight pharma advertisers are still in the running for the 2021 title. Pfizer, Bayer, Novartis, Roche, Johnson & Johnson and GlaxoSmithKline’s ViiV Healthcare are among the Big Pharma contenders still playing in the DTC ad campaign contest, while Evofem Biosciences and Biohaven Pharmaceuticals are the smaller upstarts looking for… Read More »

Novartis’ new cell therapy facility could ease manufacturing squeeze for CAR-T med Kymriah

Novartis’ big push into cell and gene therapy hasn’t been the smoothest of rides, with a data manipulation scandal hamstringing Zolgensma and manufacturing concerns hurting CAR-T cancer therapy Kymriah. Could a new European facility help turn around the latter’s production bottleneck? Novartis last week opened its newest cell and gene therapy facility in Stein, Switzerland,… Read More »

Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve

Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer. The Swiss drugmaker will roll out the drug, a one-time treatment for pediatric patients less than 2 years of… Read More »

Novartis’ slow-rolling Kymriah wins coverage in Japan at $305K: report

After snagging the first Japanese CAR-T approval in March, Novartis has won the go-ahead to sell its groundbreaking med, Kymriah, under the country’s national insurance system. And that gives the brand a chance to boost lagging sales. The Central Social Insurance Medical Council of Japan’s Ministry of Health, Labor and Welfare has approved coverage of… Read More »

Novartis abandons effort for U.S. approval of biosimilar rituximab

FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo (Reuters) – Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used… Read More »